Prior authorization depends on medical necessity and indication

Coverage and prior authorization decisions for TMS are based on demonstrated medical necessity and the specific indication; the policy lists FDA-cleared devices by indication to inform device–indication alignment during review.

• FDA clearance alone does not establish medical necessity; coverage requires demonstrated medical necessity for the indicated diagnosis.
• Providers should align requested device use with the FDA-cleared device list by indication (MDD, OCD, migraine with aura).

Prior authorization may be required for listed TMS procedure codes

Certain TMS CPT/HCPCS procedure codes are identified as affected and services billed under these codes may require prior authorization; billing rules also require physician oversight for daily TMS sessions.

• Codes specifically referenced as affected include 0889T, 0891T, 0892T, 0997T, 0998T, 0858T, and 90867 (per coding/billing section).
• Daily TMS session administration must be billed 'incident to' a supervising physician per billing guidelines.

Prior authorization and review recommended for unlisted codes

Unlisted procedure codes are subject to review for medical necessity, correct coding, and pricing; prior authorization is recommended for unlisted codes submitted for potentially covered services to avoid post-service denial.

• All unlisted codes are reviewed at the claim level for medical necessity, coding, and pricing.
• If an unlisted code is submitted for a potentially covered service, prior authorization is recommended to avoid post-service denial.

Document prior pharmacotherapy / treatment resistance

When requesting TMS for treatment-resistant depression, document prior pharmacologic trials or treatment resistance; the policy notes an emerging consensus to consider TMS after failure of at least two antidepressant medication trials.

• Document the history of prior antidepressant trials (failure to respond to at least two trials is the commonly cited threshold).
• Record whether TMS is being used as augmentation or primary therapy and relevant treatment timelines.

Position TMS after inadequate pharmacologic response (commonly ≥2 trials)

TMS is generally positioned after inadequate response to pharmacologic treatments for major depressive disorder; guidance and evidence commonly reference considering TMS after ≥2 antidepressant trials.

• VA/DoD guideline suggests offering rTMS for patients with partial or no response to an adequate trial of 2 or more pharmacologic treatments.
• Emerging consensus recommends considering TMS for patients who have failed to respond to at least two antidepressant medication trials.

Submit complete clinical documentation: indication, device, device–indication mapping, and prior treatments

Ensure required clinical and billing documentation is complete: document the indication, device used (or note experimental techniques), FDA-cleared device mapping to indication, and prior treatment history to support medical necessity.

• Document the patient diagnosis (e.g., MDD, OCD, migraine with aura) and whether treatment is augmentation or primary.
• Specify the device used and align it to the policy's list of FDA-cleared devices for the indicated condition; note if the technique/device is experimental (e.g., precuneus stimulation).
• Include prior treatment history (pharmacologic trials, durations, and outcomes) to substantiate treatment-resistance claims.

Supervising clinician must perform initial evaluation; operators require documented training

Initial evaluation and treatment planning must be performed by the supervising psychiatrist or psychiatric mental health nurse practitioner (PMHNP); device operators must have documented training and maintained competency.

• Supervising clinician must perform the initial evaluation and treatment planning directly and cannot delegate this responsibility.
• Operators should be trained in motor threshold assessment, coil positioning, patient monitoring, and emergency response and maintain documented competency.

Initial evaluation cannot be delegated; PA/NP billing must be 'incident to' supervising physician

For billing and provider roles: initial evaluation and treatment planning cannot be delegated; PAs/NPs may not bill independently for daily TMS sessions and such services must be billed 'incident to' a supervising physician per applicable billing guidelines.

• Initial evaluation and treatment planning must be performed directly by the supervising psychiatrist or PMHNP and cannot be delegated.
• Daily TMS session administration by PAs/NPs must be billed 'incident to' a supervising physician; PAs/NPs may not bill independently for these services.

Unlisted code review and denial risk for non-covered services

All unlisted codes submitted for services addressed by this policy are reviewed for medical necessity, coding accuracy, and pricing; submissions for non-covered services will be denied as not covered.

• Unlisted codes for potentially covered services: prior authorization is recommended to avoid post-service denial.
• If an unlisted code is submitted for a non-covered service addressed in this policy, it will be denied as not covered.

FDA clearance does not equal medical necessity — document clinical justification

FDA clearance alone does not establish medical necessity and is not sufficient for coverage; absence of documented medical necessity or insufficient evidence for the requested indication may result in denial.

• Approval or clearance by the FDA does not itself establish medical necessity or serve as a basis for coverage.
• Treatments lacking sufficient evidence for the requested indication or long-term benefit may be deemed not medically necessary.

PA/NP billing limits and daily TMS session billing guidance

Billing limitations and daily session billing guidance: PAs and NPs may not bill independently for TMS daily sessions (must be billed 'incident to'); initial evaluation/treatment planning must be done by the supervising psychiatrist or PMHNP and cannot be billed by delegation.

• Daily TMS session administration must be billed 'incident to' a supervising physician; PAs/NPs cannot bill independently for these services.
• Ensure billing codes reflect that initial evaluation and treatment planning were performed by the supervising psychiatrist or PMHNP.

Unlisted code submissions for non-covered services will be denied

Submission of an unlisted code for a non-covered service addressed by this policy will be denied as not covered; prior authorization is recommended for unlisted codes submitted for potentially covered services to avoid post-service denial.

• Unlisted codes submitted for non-covered services will be denied.
• Prior authorization is recommended when unlisted codes are used for potentially covered services.